HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Martin Schlesinger Selected Research

Integrin alpha4beta1 (VLA-4)

2/2021Inhibition of Tumor-Host Cell Interactions Using Synthetic Heparin Mimetics.
8/2017The matricellular ligand Cyr61 contributes to the metastatic spread of tumors by activating integrin VLA-4, independently of thiol redox modulation
.
12/2015Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis.
3/2015Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
5/2014The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
5/2012The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
1/2011Lysophosphatidylcholine pretreatment reduces VLA-4 and P-Selectin-mediated b16.f10 melanoma cell adhesion in vitro and inhibits metastasis-like lung invasion in vivo.
11/2009Binding between heparin and the integrin VLA-4.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Martin Schlesinger Research Topics

Disease

26Neoplasms (Cancer)
10/2022 - 08/2010
14Neoplasm Metastasis (Metastasis)
04/2022 - 11/2009
11Melanoma (Melanoma, Malignant)
02/2021 - 11/2009
5Ovarian Neoplasms (Ovarian Cancer)
12/2020 - 09/2015
5Breast Neoplasms (Breast Cancer)
07/2020 - 01/2018
2Pancreatic Neoplasms (Pancreatic Cancer)
03/2021 - 07/2016
2Thrombosis (Thrombus)
09/2017 - 09/2015
2Inflammation (Inflammations)
12/2015 - 01/2015
1Vascular System Injuries
04/2022
1Colorectal Neoplasms (Colorectal Cancer)
11/2021
1Prostatic Neoplasms (Prostate Cancer)
10/2018
1Embolism (Embolus)
10/2018
1Carcinogenesis
12/2015
1Sarcoma (Soft Tissue Sarcoma)
12/2015
1Neoplasm Micrometastasis
12/2015
1Atherosclerosis
01/2015
1Experimental Melanoma
05/2014
1Hemorrhage
05/2012
1Carcinoma (Carcinomatosis)
08/2010

Drug/Important Bio-Agent (IBA)

13Heparin (Liquaemin)FDA LinkGeneric
03/2021 - 11/2009
9IntegrinsIBA
02/2021 - 11/2009
8Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
10/2022 - 05/2014
8Integrin alpha4beta1 (VLA-4)IBA
02/2021 - 11/2009
7Cisplatin (Platino)FDA LinkGeneric
12/2020 - 09/2015
6P-SelectinIBA
03/2021 - 08/2010
5Collagen Type I (Type I Collagen)IBA
12/2020 - 12/2018
4AnticoagulantsIBA
10/2022 - 05/2012
4ChemokinesIBA
01/2021 - 01/2015
4Tinzaparin (Innohep)FDA Link
09/2017 - 05/2014
4Lysophosphatidylcholines (Lysophosphatidylcholine)IBA
12/2016 - 01/2011
4Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
12/2015 - 11/2009
3LigandsIBA
03/2021 - 08/2010
3heparanaseIBA
10/2018 - 05/2014
3Liposomes (Liposome)IBA
07/2016 - 01/2011
3SelectinsIBA
05/2012 - 11/2009
2Glycoproteins (Glycoprotein)IBA
04/2022 - 10/2018
2Biomarkers (Surrogate Marker)IBA
11/2021 - 12/2016
2ThrombinFDA Link
03/2021 - 01/2018
2Pharmaceutical PreparationsIBA
02/2021 - 09/2017
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2021 - 10/2018
2Adenosine Triphosphate (ATP)IBA
01/2021 - 02/2020
2Fondaparinux (Arixtra)FDA Link
02/2020 - 10/2018
2Mitoxantrone (Novantrone)FDA LinkGeneric
01/2020 - 12/2018
2Fibronectins (Fibronectin)IBA
01/2020 - 01/2011
2adhesion receptorIBA
10/2018 - 08/2010
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2018 - 01/2018
2Fatty Acids (Saturated Fatty Acids)IBA
12/2015 - 01/2011
2Chemokine ReceptorsIBA
12/2015 - 01/2015
1von Willebrand FactorIBA
04/2022
1Thrombopoietin (c-mpl Ligand)IBA
04/2022
1Insulin-Like PeptidesIBA
11/2021
11-oxo-1H-phenalene-2,3-dicarbonitrileIBA
10/2021
1Thromboplastin (Tissue Factor)IBA
03/2021
1acrylic acid (acrylate)IBA
02/2021
1PolymersIBA
02/2021
1SodiumIBA
02/2021
1Discoidin Domain Receptor 1IBA
07/2020
1Extracellular Matrix ProteinsIBA
07/2020
1GlycosaminoglycansIBA
02/2020
1Doxorubicin (Adriamycin)FDA LinkGeneric
01/2020
1PlatinumIBA
11/2019
1Estrogens (Estrogen)FDA Link
12/2018
1ProteomeIBA
12/2018
1Transcription Factors (Transcription Factor)IBA
10/2018
1Proteins (Proteins, Gene)FDA Link
10/2018
1Thrombin Receptors (Thrombin Receptor)IBA
10/2018
1Cytostatic AgentsIBA
05/2017
1Nonesterified Fatty Acids (NEFA)IBA
12/2016
1Phospholipids (Phosphatides)FDA LinkGeneric
12/2016
1CurcuminIBA
07/2016
1AgarIBA
07/2016
1GemcitabineFDA Link
07/2016
1Cytotoxins (Cytolysins)IBA
07/2016
1I-kappa B Proteins (I kappa B)IBA
07/2016
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
12/2015
1Peptides (Polypeptides)IBA
12/2015
1RNA (Ribonucleic Acid)IBA
05/2014
1L-SelectinIBA
05/2014
1galactocerebrosideIBA
08/2010
1MucinsIBA
08/2010

Therapy/Procedure

3Therapeutics
05/2017 - 09/2015
2Drug Therapy (Chemotherapy)
01/2020 - 09/2015